Trovostobart

特沃苏拜单抗

Report date: 2025/11/11 17:45:15

Base Information

Drug NameTrovostobart

Drug Alias NameKVA-12.1KVA-12123

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionV-domain Ig suppressor of T-cell activation inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants

TargetsV-domain Ig suppressor of T-cell activation

Therapy Area/IndicationsSolid tumoursKidney NeoplasmsProstatic Neoplasms +[17]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesGigaGen Inc

China Registration ClassN/A

Develop Information

Active CompaniesKineta Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursKidney NeoplasmsProstatic Neoplasms +[16]

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A